
HIMS
股票Hims & Hers Health Inc
- 总部
- US
- 行业
- 医疗保健
- 发行时间
- 2021-01-21
- 流通股
- 231M
区间表现
4 天前关键指标
4 天前- 市值
- $5.87B
- 企业价值
- $6.63B
- 市盈率 (年)
- 45.76
- 市净率
- 13.66
- 市销率 (TTM)
- 2.48
- 市销率 (年)
- 2.50
- EV / EBITDA
- 176.36×
- EV / 营收
- 2.80×
- 每股收益 (TTM)
- −$0.10
- 每股收益 (年)
- $0.50
- 基本每股收益 (TTM)
- −$0.10
- 每股净资产
- $2.38
- 毛利率
- 72.92%
- 营业利润率
- -1.29%
- 净利率
- -0.56%
- 净资产收益率 (ROE)
- -2.48%
- 总资产收益率 (ROA)
- -0.62%
- 投资回报率 (ROI)
- -0.88%
- 每股 EBITDA
- $0.15
- 每股营收 (TTM)
- $10.38
- 营收增长 (TTM YoY)
- +32.81%
- 营收增长 (季 YoY)
- +3.77%
- 流动比率
- 1.90
- 速动比率
- 1.61
- 负债权益比
- 1.80
- 长期负债权益比
- 1.80
- Beta
- 2.42
- 波动率 (3M)
- 122.04%
分析师评级
4 天前财报
4 天前相关新闻
4 天前- Yahoo·4 天前companyHims And Hers Canadian GLP 1 Push Tests Broader Wellness Subscription Thesis
Hims & Hers Health (NYSE:HIMS) has launched generic semaglutide in Canada following a key patent lapse, marking its first GLP-1 offering outside the United States. Hims & Hers Health is also expanding its Hims & Hers Benefits program, aiming to bundle access to medications with broader wellness services. Management is positioning these moves as part of a push into new international markets and more comprehensive care offerings. Hims & Hers Health, known for its telehealth platform focused...
- Yahoo·4 天前companyHIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform
CEO Andrew Dudum said Hims is building "an entire health ecosystem" rather than serving as a solution for a single health condition.
- Yahoo·5 天前companyHims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
SAN FRANCISCO, May 28, 2026--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a carefully curated lineup spanning nutrition, fitness, women's health, metabolic monitoring, and connected well
- Benzinga·5 天前companyCVS Expands GLP-1 Options For Members, Including The Reintroduction Of Zepbound As A Covered Medication
These changes build on Caremark's industry leading efforts as a pharmacy benefits manager to explore all potential avenues that help patients get FDA-approved weight management medications at an affordable cost. Plan
- Yahoo·6 天前companyHims & Hers Stock Spikes -- Insider Sends Strong Signal With $1 Million Buy
Hims & Hers Stock Pops After Board Member Makes Surprise $1.2 Million Purchase
- Yahoo·6 天前companyHims & Hers Gains 5% on Insider Buying
Director David Wells acquires 48,400 shares
- Yahoo·6 天前companyHIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?
Hims & Hers and Tempus AI are taking different paths in AI-driven healthcare, but which stock offers stronger upside now? Let's dive in.
- Yahoo·6 天前companyHims Insider Makes First Stock Purchase Since 2021 Amid Weight-Loss Drug Pivot
Hims & Hers Health shares have slumped in 2026 as the telehealth provider moves away from selling compounded GLP-1 medications.
